Re: Lunch with Annabel
Thanks for posting this link. Annabel is one of the few analysts that really understands HZNP's potential, noting that it is on the precipice of breaking through the malaise that has been plaguing the company's stock price for the past few months. Even great news does not push the needle very much. Part of the problem may be weak longs that are trading the stock for a quick profit as opposed to long term investors that agree with Annabel's view of the company. A $35 price target is fairly conservative given that K and T (when approved) are projected to generate combined annual peak sales of $1.5 billion. Those sales when combined with primary care sales of about $300 million per year and historical other rheumatology sales of about $500 million results in about $2.3 billion in annual revenue. HZNP has also put together a team to promote T once approved---the company is executing very well. What's' not to like...